Point-of-care diagnostic device

Description

FIG. 1 is a top perspective view of the point-of-care diagnostic device, as seen from the top, front, and side;

FIG. 2 is a top plan view thereof;

FIG. 3 is a front elevation view thereof;

FIG. 4 is a right side elevation view thereof;

FIG. 5 is a left side elevation view thereof;

FIG. 6 is a rear elevation view thereof;

FIG. 7 is a bottom plan view thereof; and,

FIG. 8 is a top perspective view of alternative embodiment of the point-of-care diagnostic device, showing the door slid in the open position.

The broken line depiction of a point-of-care device is included for the purpose of illustrating environmental structure and forms no part of the claimed design.

Claims

CLAIM The ornamental design for a point-of-care diagnostic device, as shown and described.

---

Inventors:	Uzri; Dina (San Diego, CA), Zin; Benedict L. (San Diego, CA), Messmer; Bradley Todd (San Diego, CA), Kim; Inhoe (San Diego, CA), Shaanan; Gad (San Diego, CA), Fecteau; Jessie-Farah (Escondido, CA)
Applicant:	Name City State Country Type Abreos Biosciences, Inc. La Jolla CA US
Assignee:	ABREOS BIOSCIENCES, INC. (San Diego, CA)
Appl. No.:	D/568,417
Filed:	June 17, 2016

---

Current U.S. Class:	D24/216
Current International Class:	2401
Field of Search:	;D24/216,107,169,186,231,232,233 ;D10/81

---

References Cited [Referenced By]

---

U.S. Patent Documents

5281395	January 1994	Markart et al.
5413764	May 1995	Haar
5567594	October 1996	Calenoff
5885577	March 1999	Alvarez
6146589	November 2000	Chandler
6210901	April 2001	Seidel et al.
7074888	July 2006	Miller et al.
8193002	June 2012	Guo et al.
8507216	August 2013	Kuroda et al.
9250233	February 2016	Kipps et al.
D774205	December 2016	Grace
2003/0068664	April 2003	Albitar et al.
2005/0084491	April 2005	Shealy et al.
2005/0191620	September 2005	McDevitt et al.
2005/0208587	September 2005	Cardoso et al.
2005/0272106	December 2005	Moore et al.
2006/0008920	January 2006	Wong et al.
2006/0068501	March 2006	Li et al.
2006/0286379	December 2006	Gao
2010/0330585	December 2010	Kabri et al.
2011/0117636	May 2011	Bae et al.
2011/0136155	June 2011	Mehra et al.
2011/0320130	December 2011	Valdes et al.
2012/0220049	August 2012	Bunce et al.
2012/0225423	September 2012	Schwoebel et al.
2013/0040401	February 2013	Zin et al.
2013/0085349	April 2013	Shaanan et al.
2013/0130404	May 2013	Mehra et al.
2013/0143246	June 2013	Nelson et al.
2015/0293086	October 2015	Messmer et al.
2015/0301031	October 2015	Zin et al.
2016/0146829	May 2016	Kipps et al.

Foreign Patent Documents

	WO-2007022557		Mar 2007		WO
	WO-2009121024		Oct 2009		WO
	WO-2012023053		Feb 2012		WO
	WO-2015160834		Oct 2015		WO
	WO-2016123105		Aug 2016		WO

Other References

Colman et al. Effects of amino acid sequence changes on antibody-antigen interactions. Research in Immunology 145(1):33-36 (1994). cited by applicant . Dalakas et al. Effect of Alemtuzumab (Campath 1H) in patients with inclusion-body myositis. Brain 132:1536-1544 (2009). cited by applicant . Harlow et al. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 23-26 (1988). cited by applicant . Lederman et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol 28(11):1171-1181 (1991). cited by applicant . U.S. Appl. No. 14/686,578 Office Action dated Oct. 14, 2016. cited by applicant . U.S. Appl. No. 14/981,715 Office Action dated Jul. 12, 2016. cited by applicant . McDade et al. What a Drop Can Do: Dried Blood Spots As a Minimally Invasive Method for Integrating Biomarkers into Population Based Research. Demography 44(4):899-925 (2007). cited by applicant . PCT/US2015/025796 International Preliminary Report on Patentability dated Oct. 27, 2016. cited by applicant . U.S. Serial No. 14/981,715 Office Action dated Jan. 19, 2017. cited by applicant . U.S. Serial No. 15/185,549 Office Action dated Jan. 6, 2017. cited by applicant . Adams et al. Monoclonal antibody therapy of cancer. Nat Biotechnol. 23:1147-1157 (2005). cited by applicant . Barenholz et al. A peptide mimetic of the mycobacterial mannosylated lipoarabinomannan: characterization and potential applications. J Med Microbiol 56(pt 5):579-586 (2007). cited by applicant . Barnett et al. In-Field Implementation of a Recombinant Factor C Assay for the Detection of Lipopolysaccharide as a Biomarker of Extant Life within Glacial Environments. Biosensors (Basel) 2(1):83-100 (2012). cited by applicant . Bazin et al. Rapid visual tests: fast and reliable detection of ochratoxin A. Toxins (Basel) 2(9):2230-2241 (2010). cited by applicant . Beum et al. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods 289(1-2)97-109 (2004). cited by applicant . Blasco et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immun Methods 325(1-2):127-139 (2007). cited by applicant . Breidenbach et al. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432(7019):925-929 (2004). cited by applicant . Brissette et al. Identification of cancer targets and therapeutics using phage display. Curr Opin Drug Discov Devel 9:363-369 (2006). cited by applicant . Carpino et al. 9-Fluorenylmethoxycarbonyl amino-protecting group. J Org Chem 37(22)3404-3409 (1972). cited by applicant . Co-pending U.S. Appl. No. 15/185,549, filed Jun. 17, 2016. cited by applicant . Co-pending U.S. Appl. No. 29/568,418, filed Jun. 17, 2016. cited by applicant . Degardin et al. Understanding and fighting the medicine counterfeit market. J Pharm Biomed Anal 87:167-175 (2013). cited by applicant . Delano et al. Convergent solutions to binding at a protein-protein interface. Science 287(5456):1279-1283 (2000). cited by applicant . Ding et al. Endotoxin detection--from limulus amebocyte lysate to recombinant factor C. Subcell Biochem 53:187-208 (2010). cited by applicant . FDA--definition of biological product. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopeda- ndApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.- htm (Jul. 2015). cited by applicant . Feltrup et al. Development of a fluorescence internal quenching correction factor to correct botulinum neurotoxin type a endopeptidase kinetics using SNAPtide. Anal Chem 84(24):10549-10553 (2012). cited by applicant . Fernandez-Salas et al. Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay. PLoS One 7(11):e49516 (2012). cited by applicant . Golden et al. Extended result reading window in lateral flow tests detecting exposure to Onchocerca volvulus: a new technology to improve epidemiological surveillance tools. PLoS One 8(7):e69231 (2013). cited by applicant . Hale et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104(4):948-955 (2004). cited by applicant . Hale. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology 1(3-4):175-187 (1995). cited by applicant . Jiang et al. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2 J Biol Chem 280(6):4656-4662 (2004). cited by applicant . Jilani et al. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res 28(12):1255-1262 (2004). cited by applicant . Joiner et al. Comparison of Endotoxin Testing Methods for Pharmaceutical Products. Int J Pharm Compd 6:408-409 (2002). cited by applicant . Jones et al. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J Immunol Meth 329(1-2):92-101 (2008). cited by applicant . Kosik et al. Studies of enzymatic cleavage of cellulose using polysaccharide analysis by carbohydrate gel electrophoresis (PACE). Methods Enzymol 510:51-67 (2012). cited by applicant . Laderman et al. Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood. Clin Vaccine Immunol. 15(1):159-163 (2007). cited by applicant . Lee et al. Performance improvement of the one-dot lateral flow immunoassay for aflatoxin B1 by using a smartphone-based reading system. Sensors (Basel) 13(4):5109-5116 (2013). cited by applicant . Lonza Limulus Amebocyte Lysate (LAL) QCL-1000. Available from: http://bio.lonza.com/uploads/txmwaxmarketingmaterial/Lonza ManualsProductInstructions CL-1000 Product Insert.pdf (2007). cited by applicant . Maloney et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6):2188-2195 (1997). cited by applicant . Manshouri et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101(7):2507-2513 (2002). cited by applicant . Merrifield. Solid Phase Peptide Synthesis I. J Am Chem Soc 85:2149-2154 (1963). cited by applicant . Messmer et al. Specific blocking to improve biopanning in biological samples such as serum and hybridoma supernatants. Biotechniques 30(4):798-802 (2001). cited by applicant . Messmer et al. Two human neonatal IgM antibodies encoded by different variable-region genes bind the same linear peptide: evidence for a stereotyped repertoire of epitope recognition. J Immun 162(4):2184-2192 (1999). cited by applicant . Montagna et al. A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab determination: development, validation and application. Int J Immunopathol Pharmacol 20(2):363-371 (2007). cited by applicant . Mulvaney et al. Incorporating fluorescent dyes and quantum dots into magnetic microbeads for immunoassays. Biotechniques. 36(4):602-609 (2004). cited by applicant . Nakamura et al. Lipopolysaccharide-sensitive serine-protease zymogen (factor C) found in Limulus hemocytes. Isolation and characterization. Eur J Biochem 154:511-521 (1986). cited by applicant . Nakano et al. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. J Immunol Methods 293:183-189 (2004). cited by applicant . Ouimet et al. Comparison of Fluorigenic Peptide Substrates PL50, SNAPtide, and BoTest A/E for BoNT/A Detection and Quantification: Exosite Binding Confers High-Assay Sensitivity. Journal of Biomolecular Screening 18(6):726-735 (2013). cited by applicant . PCT/US2009/038674 International Preliminary Report on Patentability dated Sep. 28, 2010. cited by applicant . PCT/US2009/038674 International Search Report and Written Opinion dated Dec. 24, 2009. cited by applicant . PCT/US2015/025796 International Search Report and Written Opinion dated Aug. 21, 2015. cited by applicant . PCT/US2016/14924 International Search Report and Written Opinion dated Apr. 8, 2016. cited by applicant . Perosa et al. Identification of an antigenic and immunogenic motif expressed by two 7-merrituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J Immunol 179(11):7967-7974 (2007). cited by applicant . Pierce.RTM. LAL Chromogenic Endotoxin Quantitation Kit. Available from: https://www.piercenet.com/instructions/2162445.pdf (2013). cited by applicant . Poras et al. Detection and Quantification of Botulinum Neurotoxin Type A by a Novel Rapid In Vitro Fluorimetric Assay. Applied and Environmental Microbiology 75(13):4382-4390 (2009). cited by applicant . Rebello et al. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 260(1-2):285-302 (2002). cited by applicant . Rohr et al. Immunoassay employing surface-enhanced Raman spectroscopy. Anal Biochem 182(2):388-398 (1989). cited by applicant . Sanchez et al. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol 66(5):919-925 (2010). cited by applicant . Shin et al. Combinatorial solid phase peptide synthesis and bioassays. J Biochem Mol Biol 38(5):517-525 (2005). cited by applicant . Sosnick et al. Distances between the antigen-binding sites of three murine antibody subclasses measured using neutron and X-ray scattering. Biochemistry 31:1779-1786 (1992). cited by applicant . Tan et al. Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors. Clin Cancer Res. 12(21):6517-6522 (2006). cited by applicant . Tian et al. Antigen peptide-based immunosensors for rapid detection of antibodies and antigens. Anal Chem 81(13):5218-5225 (2009). cited by applicant . Titov et al. Development and optimization of immunoassays for the detection of botulinum toxins. Prikl Biokhim Mikrobiol 48(2):249-256 (2012). cited by applicant . Tokunaga et al. Further studies on lipopolysaccharide-sensitive serine protease zymogen (factor C): its isolation from Limulus polyphemus hemocytes and identification as an intracellular zymogen activated by alpha-chymotrypsin, not by trypsin. J Biochem 109:150-157 (1991). cited by applicant . U.S. Serial No. 12/934,624 Office Action dated Aug. 22, 2014. cited by applicant . U.S. Serial No. 12/934,624 Office Action dated Jan. 8, 2014. cited by applicant . U.S. Serial No. 12/934,624 Office Action dated Mar. 27, 2015. cited by applicant . Wang et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology 120(2):355-361 (2013). cited by applicant . Williams et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 177:7435-7443 (2006). cited by applicant.

Primary Examiner: Laymon; Wan
Assistant Examiner: Booker; Mark
Attorney, Agent or Firm: Wilson Sonsini Goodrich & Rosati